This body of work suggests that enhancing Flt3 signaling with exogenous Flt3L, specifically among host DCs, results in regulatory DCs that limit alloreactive T-cell responses, are less pro-inflammatory, and prevent GvHD. Here, FLT3 is linked to graft versus host disease.